FIELD: pharmaceutical chemistry.
SUBSTANCE: group of inventions includes an ENPP1 inhibitor of formula (VI) and a pharmaceutical composition based on it. In formula (VI), X is selected from ,
,
,
,
and
; L is selected from -CH2 - and -(CH2)2-; each of Z1 and Z2 is independently selected from CR1 and N; each of Z3 and Z4 is independently selected from CR and N, where R is H; each R1 is independently selected from H and alkenyl having 2 to 6 carbon atoms substituted with pyridine; each of R2 and R5 is independently selected from H, OH, alkoxy containing from 1 to 6 carbon atoms, and halogen; each of R3 and R4 is independently selected from H, OH, alkoxy containing from 1 to 6 carbon atoms, halogen and amino; or R3 and R4 together with the carbon atoms to which they are attached form dioxane.
(VI)
EFFECT: compound of formula (VI) with inhibitory activity against ENPP1.
13 cl, 11 dwg, 4 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | 2019 |
|
RU2797622C2 |
MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
VET PROTEIN DECOMPOSERS | 2017 |
|
RU2752677C2 |
N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF | 2016 |
|
RU2735522C2 |
N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
MEK INHIBITORS AND THEIR THERAPEUTIC USE | 2021 |
|
RU2812929C1 |
AMPK LOW-MOLECULAR ACTIVATORS | 2017 |
|
RU2766146C2 |
SPIRO OXINDOLE MDM2 ANTAGONISTS | 2010 |
|
RU2553269C2 |
Authors
Dates
2023-07-28—Published
2018-09-07—Filed